WO2009024771A3 - Materials and methods for treating cancers which express folate receptors - Google Patents

Materials and methods for treating cancers which express folate receptors Download PDF

Info

Publication number
WO2009024771A3
WO2009024771A3 PCT/GB2008/002799 GB2008002799W WO2009024771A3 WO 2009024771 A3 WO2009024771 A3 WO 2009024771A3 GB 2008002799 W GB2008002799 W GB 2008002799W WO 2009024771 A3 WO2009024771 A3 WO 2009024771A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
materials
antibody
treating cancers
conjugate
Prior art date
Application number
PCT/GB2008/002799
Other languages
French (fr)
Other versions
WO2009024771A2 (en
Inventor
Colin Henry Self
Stephen Thompson
Original Assignee
Biotransformations Ltd
Colin Henry Self
Stephen Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransformations Ltd, Colin Henry Self, Stephen Thompson filed Critical Biotransformations Ltd
Publication of WO2009024771A2 publication Critical patent/WO2009024771A2/en
Publication of WO2009024771A3 publication Critical patent/WO2009024771A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention provides antibody conjugates comprising an antibody binding domain specific for CD3, a folate receptor ligand capable of binding to a folate receptor and a photocleavable moiety which inhibits binding of the antibody binding domain to CD3. The antibody conjugates may be used in methods of treating cancer, wherein one or more of the cells of the cancer express folate receptor. The invention also provides a method of killing a cancer cell by contacting the cancer cell with an antibody conjugate of the invention, irradiating the conjugate to cleave the photocleavable moiety from the conjugate and contacting the cancer cell with a T cell.
PCT/GB2008/002799 2007-08-17 2008-08-18 Materials and methods for treating cancers which express folate receptors WO2009024771A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716160.7A GB0716160D0 (en) 2007-08-17 2007-08-17 Materials and methods for treating cancers which express folate receptors
GB0716160.7 2007-08-17

Publications (2)

Publication Number Publication Date
WO2009024771A2 WO2009024771A2 (en) 2009-02-26
WO2009024771A3 true WO2009024771A3 (en) 2009-07-30

Family

ID=38566627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002799 WO2009024771A2 (en) 2007-08-17 2008-08-18 Materials and methods for treating cancers which express folate receptors

Country Status (2)

Country Link
GB (1) GB0716160D0 (en)
WO (1) WO2009024771A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2915412A1 (en) * 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
TW201446804A (en) * 2013-05-14 2014-12-16 Ambrx Inc Novel polypeptide small molecule conjugates and their uses
JP6545666B2 (en) 2013-05-28 2019-07-17 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ Antibody locker for protein drug inactivation
GB2528643A (en) * 2014-07-08 2016-02-03 Adc Biotechnology Ltd Method of synthesising ADCs
JP2018508481A (en) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム Targeted partial peptide epitope complex having multiple T cell epitopes
KR20180077271A (en) * 2015-11-03 2018-07-06 암브룩스, 인코포레이티드 Anti-CD3-Folate conjugates and uses thereof
PT3377103T (en) 2015-11-19 2021-05-26 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
MA48608A (en) 2016-12-09 2020-03-18 Seattle Genetics Inc BIVALENT ANTIBODIES MASKED BY WOUND COILS
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
WO1996034892A1 (en) * 1995-05-03 1996-11-07 Bioenhancements Ltd. Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
WO2005083431A2 (en) * 2004-02-25 2005-09-09 Bloenhancements Limited Binding agents
WO2007107764A1 (en) * 2006-03-21 2007-09-27 Biotransformations Limited Reversibly inhibited antibodies for immune cell stimulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034892A1 (en) * 1995-05-03 1996-11-07 Bioenhancements Ltd. Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
WO2005083431A2 (en) * 2004-02-25 2005-09-09 Bloenhancements Limited Binding agents
WO2007107764A1 (en) * 2006-03-21 2007-09-27 Biotransformations Limited Reversibly inhibited antibodies for immune cell stimulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROY E J ET AL: "Folate-mediated targeting of T cells to tumors", ADVANCED DRUG DELIVERY REVIEWS 20040429 NL, vol. 56, no. 8, 29 April 2004 (2004-04-29), pages 1219 - 1321, XP002528142, ISSN: 0169-409X *
THOMPSON ET AL: "The construction and in vitro testing of photo-activatable cancer targeting folated anti-CD3 conjugates", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 366, no. 2, 31 December 2007 (2007-12-31), pages 526 - 531, XP022404906, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2009024771A2 (en) 2009-02-26
GB0716160D0 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
WO2009024771A3 (en) Materials and methods for treating cancers which express folate receptors
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
WO2009140177A3 (en) Anti-fn14 antibodies and uses thereof
WO2008120202A3 (en) Antibodies, methods and kits for diagnosing and treating melanoma
WO2010045598A3 (en) Psma binding ligand-linker conjugates and methods for using
TW200609506A (en) Methods and systems for detecting biomolecular binding using terahertz radiation
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007126805A3 (en) Cancer immunotherapy compositions and methods of use
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
IN2009KN02404A (en)
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
WO2005116236A3 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
CU23809A3 (en) PRLR SPECIFIC ANTIBODY
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
TR201820015T4 (en) Using Chimeric Antigen Receptor-Modified T Cells for Cancer Treatment
WO2007059297A8 (en) Multimeric biosensors and methods of using the same
EP2210939A4 (en) Anti-bst2 antibody
EA201190210A1 (en) INHIBITORS FOR KINASE BINDING WITH THE PROTEIN

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788366

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788366

Country of ref document: EP

Kind code of ref document: A2